IntelliPharma

We operate in the niche market created by the expiration of drug product patents and drug product exclusivity periods.

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Announces Settlement Agreement in Class Action Lawsuit, Which is Subject to Court Approval

https://t.co/3PDlM9Ggrb

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Update on its Oxycodone ER New Drug Application

https://t.co/KvHOerMl12

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Announces Third Quarter 2019 Results

https://t.co/ZEcRhstz5E

#AbuseDeterrent #Opioids #Pharma #Intelli #IPCI #CBD

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Announces an Update in the Purdue Litigation

https://t.co/RP6VnJCJBZ

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Signs a Second Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.
https://t.co/c9FbO80AZw

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.
https://t.co/GCbitf9OGQ

[IntelliPharma @IPCIPharma]

Intellipharmaceutics International Inc. Announces Update on its Oxycodone ER New Drug Application

https://t.co/6mmyEjPZtr
#AbuseDeterrent #opioids #Controlled #Release #DrugTech #Drug #Tech #Pharma #IPCI #IPCIPharma #Intelli #Odidi #FDA

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Announces Second Quarter 2019 Results

https://t.co/poyeLEvANP

#AbuseDeterrent #opioids #Controlled #Release #DrugTech #Drug #Tech #Pharma #IPCI #IPCIPharma #Intelli #Odidi #PharmaInvest

[IntelliPharma @IPCIPharma]

Intellipharmaceutics International Inc. Announces $10,000,000 Equity Financing Commitment
https://t.co/1o1FbdvJa0
#AbuseDeterrent #opioids #Controlled #Release #DrugTech #Drug #Tech #Pharma #IPCI #IPCIPharma #Intelli #Odidi #PharmaInvest

[PCG Advisory Group @PCGAdvisory]

$IPCI Intellipharmaceutics @IPCIPHARMA presenting live at @theLDMicro #LDMICRO

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Announces Receipt of Cannabis Drug License from Health Canada
https://t.co/AwvrlweuXC

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Reports Director Election Results
https://t.co/dSPNC39peD

[IntelliPharma @IPCIPharma]

Intellipharmaceutics to present at the 9th Annual LD Micro Invitational
https://t.co/6Z47n3ZmUH

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Announces FDA Approval for Generic Pristiq(R)
https://t.co/HvUrGniHap

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Closes US$1.05 Million Convertible Debenture Financing with Drs. Isa and Amina Odidi
https://t.co/wVnJASa9JH

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Announces an Update in the Purdue Litigation
https://t.co/XFkAx3Vu7Y #IPCI #ControlledRelease #Opioid #Pharmaceutical #Pharma

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Announces First Quarter 2019 Results
https://t.co/72svsGn0rr

[IntelliPharma @IPCIPharma]

FDA Acknowledges Receipt of Complete Resubmission for IPCI Oxycodone ER New Drug Application
https://t.co/ubklRiDlhp

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Receives Nasdaq Listing Determination; To Begin Trading on the OTC Markets System
https://t.co/D6TZ1dYmHU

[IntelliPharma @IPCIPharma]

Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
https://t.co/zSVropGmUn